Question from Deputy Pádraig Rice - PQ 44013-26
Deputy Rice asked about an update on an application for pricing and reimbursement of Omaveloxolone, sold under the brand name Skyclarys. Read the HSE response.
From: Communications and public affairs
Published: June 2026
Updated: July 2026
Documents
Summary
To ask the Minister for Health further to Parliamentary Question No. 566 of 21 April 2026, to provide an update on an application for pricing and reimbursement (details supplied -
Omaveloxolone [sold under the brand name Skyclarys]); if the company has submitted a proposal to the HSE’s corporate pharmaceutical unit; if the company has met with the HSE since making an offer; the steps being taken to urgently progress a decision on this application; and if she will make a statement on the matter.
This is a beta version - your feedback will help us to improve it